Erythropoietin regulates metabolic response in mice via receptor expression in adipose tissue, brain, and bone
Noguchi CT.
Narrative Review on Chronic Kidney Disease, Chronic Inflammation, published in Exp Hematol (2020) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Narrative Review
- Journal
- Exp Hematol (2020)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 32950599
- PMCID
- PMC7738372
- DOI
- 10.1016/j.exphem.2020.09.190
- Citations
- 8
Abstract (original English)
Erythropoietin (EPO) acts by binding to erythroid progenitor cells to regulate red blood cell production. While EPO receptor (Epor) expression is highest on erythroid tissue, animal models exhibit EPO activity in nonhematopoietic tissues, mediated, in part, by tissue-specific Epor expression. This review describes the metabolic response in mice to endogenous EPO and EPO treatment associated with glucose metabolism, fat mass accumulation, and inflammation in white adipose tissue and brain during diet-induced obesity and with bone marrow fat and bone remodeling. During high-fat diet-induced obesity, EPO treatment improves glucose tolerance, decreases fat mass accumulation, and shifts white adipose tissue from a pro-inflammatory to an anti-inflammatory state. Fat mass regulation by EPO is sex dimorphic, apparent in males and abrogated by estrogen in females. Cerebral EPO also regulates fat mass and hypothalamus inflammation associated with diet-induced obesity in males and ovariectomized female mice. In bone, EPO contributes to the balance between adipogenesis and osteogenesis in both male and female mice. EPO treatment promotes bone loss mediated via Epor in osteoblasts and reduces bone marrow adipocytes before and independent of change in white adipose tissue fat mass. EPO regulation of bone loss and fat mass is independent of EPO-stimulated erythropoiesis. EPO nonhematopoietic
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level ASystematic ReviewEurope PMC
Exosomes in diabetic kidney disease: pathogenesis, biomarker discovery, and emerging therapeutics-a comprehensive systematic review
Systematic Review on Chronic Kidney Disease, published in Ren Fail (2026) — summary generated from the PubMed abstract.
- 2026
Ren Fail - Level AMeta-analysisEurope PMC
Meta-analysis study of the therapeutic impact of Mesenchymal stem cells derived exosomes for chronic kidney diseases
Meta-analysis on Chronic Kidney Disease, published in Biochem Biophys Rep (2025) — summary generated from the PubMed abstract.
- 2025
Biochem Biophys Rep2 citations - Level ASystematic ReviewPubMed
Clinical Safety and Efficacy of Allogeneic Adipose Stem Cells: A Systematic Review of the Clinical Trials.
Systematic Review with a reported sample of 953 on Osteoarthritis, Chronic Kidney Disease, Scar, Autoimmune Research, published in Int J Mol Sci (2025) — summary generated from the PubMed abstract.
- 2025
- n = 953
Int J Mol Sci2 citations - Level ASystematic ReviewEurope PMC
Worldwide hotspots and trends in stem cell therapy for kidney disease in the last decade: a bibliometric and visualization analysis from 2015 to 2024
Systematic Review on Chronic Kidney Disease, Acute Kidney Injury, published in Front Immunol (2025) — summary generated from the PubMed abstract.
- 2025
Front Immunol2 citations - Level AMeta-analysisEurope PMC
Mesenchymal Stem Cells as Anti-Inflammatory Agents in Chronic Kidney Disease: A Systematic Review and Meta-Analysis
Meta-analysis on Chronic Kidney Disease, Chronic Inflammation, published in Cells (2025) — summary generated from the PubMed abstract.
- 2025
Cells - Level AMeta-analysisEurope PMC
Protective role of exosomes in renal ischemia-reperfusion injury: a systematic review and meta-analysis
Meta-analysis on Chronic Kidney Disease, Acute Kidney Injury, published in Front Pharmacol (2025) — summary generated from the PubMed abstract.
- 2025
Front Pharmacol1 citations